Yumanity Therapeutics Profit Margin

The latest profit margin for YMTX is -177.46% as of March 2025. That compares with -2173.27% in the prior-year period — up 91.8% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Yumanity Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, YMTX's profit margin moved from -2173.27% to -177.46% — a 91.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Yumanity Therapeutics's valuation or profitability profile.

Against Healthcare companies, YMTX currently prints -177.46% for profit margin, while the sector average sits near 15.29%. That is roughly 1260.4% below the sector mean. Large gaps often invite a closer look at Yumanity Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Yumanity Therapeutics converts resources into returns. At -177.46%, YMTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -2173.27% in the prior-year period — up 91.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting YMTX's profit margin (-177.46%), review year-over-year change from -2173.27%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.